The Variable Expression of a Novel MBD5 Gene Frameshift Mutation in an Italian Family

Abstract

Haploinsufficiency of the methyl-CpG-binding domain protein 5 (MBD5) gene is reported as a cause of an autosomal dominant type of cognitive disability (MRD1) and autism spectrum disorder through large deletions involving multiple genes or point mutations, ultimately leading to haploinsufficiency in both cases. However, relatively few reports have been published on the phenotypical spectrum resulting from point mutations.

We report here on a novel heterozygous frameshift variant in the MBD5 gene [c.2579del; p.(Lys860Argfs*11)] in a family in which the typical signs associated with pathogenic variants were expressed with different degrees of severity in the clinical presentation of the carrier individuals.

Our findings, adding a novel mutation to the mutational spectrum, further support the relevance of the MBD5 gene as one of the main molecular mechanisms involved in the pathogenesis of intellectual disability and contribute to the characterization of the genotype–phenotype correlations.

Keywords

MBD5 - autism spectrum disorder - variable expression - point mutation

Publikationsverlauf

Eingereicht: 13. Dezember 2019

Angenommen: 26. Mai 2020

Artikel online veröffentlicht:
29. Dezember 2020

• References

• 1 van Bon BW, Koolen DA, Brueton L. et al. The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype. Eur J Hum Genet 2010; 18 (02) 163-170
• 2 Talkowski ME, Mullegama SV, Rosenfeld JA. et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet 2011; 89 (04) 551-563
• 3 Mullegama SV, Elsea SH. Clinical and molecular aspects of MBD5-associated neurodevelopmental disorder (MAND). Eur J Hum Genet 2016; 24 (09) 1235-1243
• 4 Luciano M, Hagenaars SP, Davies G. et al. Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. Nat Genet 2018; 50 (01) 6-11
• 5 Camarena V, Cao L, Abad C. et al. Disruption of Mbd5 in mice causes neuronal functional deficits and neurobehavioral abnormalities consistent with 2q23.1 microdeletion syndrome. EMBO Mol Med 2014; 6 (08) 1003-1015
• 6 Kleefstra T, Kramer JM, Neveling K. et al. Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. Am J Hum Genet 2012; 91 (01) 73-82
• 7 Han JY, Lee IG, Jang W. et al. Diagnostic exome sequencing identifies a heterozygous MBD5 frameshift mutation in a family with intellectual disability and epilepsy. Eur J Med Genet 2017; 60 (10) 559-564
• 8 Verhoeven W, Egger J, Kipp J. et al. A novel MBD5 mutation in an intellectually disabled adult female patient with epilepsy: suggestive of early onset dementia?. Mol Genet Genomic Med 2019; 7 (08) e849
• 9 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 10 Woodbury-Smith M, Nicolson R, Zarrei M. et al. Variable phenotype expression in a family segregating microdeletions of the NRXN1 and MBD5 autism spectrum disorder susceptibility genes. NPJ Genom Med 2017; 2: 17
• 11 Bonnet C, Ali Khan A, Bresso E. et al. Extended spectrum of MBD5 mutations in neurodevelopmental disorders. Eur J Hum Genet 2013; 21 (12) 1457-1461